Isabel Rubio, MD, PhD, Clinica Universidad de Navarra, Madrid, Spain, discusses why lymph node dissection may not be necessary prior to treatment with adjuvant therapies for breast cancer. Following the results of the MonarchE trial (NCT03155997), axillary lymph node dissection in patients with one or two positive sentinel nodes has been stopped to reduce morbidity. Instead, patients are treated with other adjuvant therapies such as CDK4/6 inhibitors. Surgery may still be useful in patients with more than two positive sentinel nodes, though other forms of surgery may be considered. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.